Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJVN89)

• Drug Name: AEB07 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Transplant rejection	NE84	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9963383
  TTD Drug ID: DMJVN89

Molecule-Related Drug Atlas

Drug(s) Targeting Protein kinase C (PRKC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Synthetic hypericin	DMXU4ON	Virus infection	1A24-1D9Z	Phase 3	[2]
APH-0812	DM756GE	Human immunodeficiency virus-1 infection	1C62	Phase 2	[3]
CYCLOPLATAM	DMXR8WN	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
HO/03/03	DMA6HQJ	Diabetic foot ulcer	BD54	Phase 2	[5]
Bryostatin-1	DM1JOXY	Alzheimer disease	8A20	Phase 2	[6]
LXS196	DM65MEL	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
SAFINGOL	DMBGUDR	Psoriasis vulgaris	EA90	Phase 1	[8]
GCC-1290K	DMJ7WRI	Parkinson disease	8A00.0	Phase 1	[9]
AEB701	DM8I4G0	Melanoma	2C30	Phase 1	[10]
Tecadenoson	DM9T6MS	Atrial fibrillation	BC81.3	Discontinued in Phase 3	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein kinase C (PRKC)	TTYVX59	NOUNIPROTAC	Inhibitor	[1]

References

• [1] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [2] Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
• [3] Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
• [4] Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
• [5] WO patent application no. 2014,0853,81, Pharmaceutical combinations.
• [6] Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
• [9] Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
• [10] Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
• [11] Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.